Effective Post-insult Neuroprotection by a Novel Ca2+/ Calmodulin-dependent Protein Kinase II (CaMKII) Inhibitor*

  1. K. Ulrich Bayer,3
  1. From the Department of Pharmacology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045 and
  2. the §Department of Neurosciences, Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29425
  1. 3 To whom correspondence should be addressed. E-mail: ulli.bayer{at}ucdenver.edu.

Abstract

Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of physiological glutamate signaling involved in higher brain functions. Here, we show CaMKII involvement in pathological glutamate signaling relevant in stroke. The novel inhibitor tatCN21 was neuroprotective even when added hours after glutamate insults. By contrast, the “traditional” inhibitor KN93 attenuated excitotoxicity only when present during the insult. Both inhibitors efficiently blocked Ca2+/CaM-stimulated CaMKII activity, CaMKII interaction with NR2B and aggregation of CaMKII holoenzymes. However, only tatCN21 but not KN93 blocked the Ca2+-independent “autonomous” activity generated by Thr-286 autophosphorylation, the hallmark feature of CaMKII regulation. Mutational analysis further validated autonomous CaMKII activity as the drug target crucial for post-insult neuroprotection. Overexpression of CaMKII wild type but not the autonomy-deficient T286A mutant significantly increased glutamate-induced neuronal death. Maybe most importantly, tatCN21 also significantly reduced infarct size in a mouse stroke model (middle cerebral arterial occlusion) when injected (1 mg/kg intravenously) 1 h after onset of arterial occlusion. Together, these data demonstrate that inhibition of autonomous CaMKII activity provides a promising therapeutic avenue for post-insult neuro-protection after stroke.

Footnotes

  • * This work was supported, in whole or in part, by National Institutes of Health Grants P30NS048154 (University of Colorado, Denver, center grant), P20RR017677-08, and R01NS052644 (to K. U. B.). This work was also supported by Veterans Affairs Merit Review (to M. S. K.) and State of Colorado TTO BDEGP. The University of Colorado is currently seeking patent protection for tatCN21 and its uses.

  • 1 Supported by National Institutes of Health Training Grant F31NS061584.

  • 2 Supported by National Institutes of Health Training Grant T32GM007635.

  • Received November 24, 2009.
  • Revision received April 26, 2010.
Table of Contents

This Article

  1. The Journal of Biological Chemistry 285, 20675-20682.
  1. All Versions of this Article:
    1. M109.088617v1
    2. 285/27/20675 (most recent)

Classifications

Article Usage Stats

Submit your work to JBC.

You'll be in good company.